Welcome to our dedicated page for AC Immune SA news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune SA stock.
AC Immune SA develops precision therapeutics and diagnostics for neurodegenerative diseases driven by misfolded proteins. The clinical-stage biopharmaceutical company uses its SupraAntigen® and Morphomer® platforms to advance active immunotherapies, small molecules, antibodies, vaccines and diagnostic programs for Alzheimer’s disease, Parkinson’s disease and NeuroOrphan indications.
Company news commonly covers clinical updates for ACI-24 in the ABATE Alzheimer’s disease study, ACI-7104.056 in the VacSYn Parkinson’s disease trial, ACI-19764 as an NLRP3 inflammasome inhibitor, and Tau Morphomer® small-molecule programs. Updates also include collaboration activity with global pharmaceutical partners, milestone payments, symposium presentations, financial results and cash runway disclosures.
AC Immune SA (NASDAQ: ACIU) has advanced to the second highest dosing group in its Phase 1b/2a clinical trial for ACI-35.030, an investigational vaccine targeting Alzheimer’s disease. This decision follows promising interim results showing safety, tolerability, and immunogenicity. ACI-35.030 aims to generate an antibody response against pathological phospho-Tau proteins, potentially mitigating Tau pathology. The trial will assess safety, tolerability, and clinical outcomes over 48 weeks. This vaccine builds on previous successes and is developed in collaboration with Janssen Pharmaceuticals.
AC Immune SA (NASDAQ: ACIU) and Life Molecular Imaging announced the publication of clinical results for the Tau-PET tracer PI-2620, showing its potential in diagnosing progressive supranuclear palsy (PSP). Published in JAMA Neurology, the study indicates that PI-2620 allows improved detection of Tau protein deposits associated with PSP, potentially leading to earlier and more accurate diagnoses. The tracer has already exhibited effectiveness in detecting Tau pathology in Alzheimer's disease. This development enhances the diagnostic capabilities for neurodegenerative disorders and could influence future therapeutic interventions.
AC Immune (NASDAQ: ACIU) announced that shareholders approved all resolutions at the Annual General Meeting held on June 26, 2020, in Lausanne, Switzerland. Board members including Douglas Williams and Martin Velasco were re-elected. The company is progressing on five clinical readouts in 2020, particularly a Phase 2 trial for its anti-Tau antibody, semorinemab, in Alzheimer's disease. Additionally, AC Immune reported a robust financial position, fully funded through Q1 2024, and has successfully adapted its operations during the Covid-19 outbreak, maintaining workflow continuity.
AC Immune SA (NASDAQ: ACIU) announced participation at the UBS Virtual Global Healthcare Conference scheduled for May 20, 2020. CEO Prof. Andrea Pfeifer will present advancements in therapies targeting TDP-43 and alpha-synuclein, key players in neurodegenerative diseases such as Alzheimer's and Parkinson's. The company highlights its proprietary platforms, SupraAntigen™ and Morphomer™, which drive innovations in therapeutics and diagnostics. AC Immune aims to enhance early diagnosis and treatment precision in neurodegenerative disorders, supported by collaborations with major pharmaceutical companies.
Summary not available.